Tumor Necrosis Factor (TNF) Inhibitor Drugs Market is growing rapidly with Novartis receiving the U.S. Food and Drug Administration (FDA) approval for its Cosentyx for the treatment of active non-radiographic axial spondyloarthritis

 

Tumor Necrosis Factor Inhibitor Drugs are drugs that have the ability to restrict or prevent the further growth of tumors. Tumor Necrosis Factor, or TNF, is a chemical neurotransmitter in the body that plays a key role in the inflammatory response of tumors. When TNF is not sufficiently regulated, tumors may grow unchecked. A TNF inhibitor, therefore, is a medical drug that inhibits the inflammatory response to tumor necrosis factor. When it comes to regional impact, North America seems to be witnessing significant growth in the tumor necrosis factor (TNF) inhibitor drugs market. This is typically due to the fact that there is the presence of key manufacturers as well as favorable reimbursement policies. On the contrary, Asia Pacific seems to be gaining robust traction since there is an emerging trend of biosimilars in emerging economies such as India, China, and South Korea.

Over the years, the demand for TNF inhibitor drugs has increased, which is typically due to rising cases of autoimmune disorders. Autoimmune disorders such as psoriasis, type1 diabetes mellitus, rheumatoid arthritis, and multiple sclerosis. As per the Centers for Disease Control and Prevention (CDC), from 2013-2015, around 54.4 million U.S. adults has some form of arthritis such as rheumatoid arthritis, gout, and lupus. TNF inhibitors help stop inflammation and aids in diseases such as rheumatoid arthritis, Crohn’s disease, and psoriatic arthritis. Thus, such factors can augment growth of the tumor necrosis factor (TNF) inhibitor drugs market.

Tumor Necrosis Factor Inhibitor Drugs can be administered to patients with inflammatory bowel diseases such as ulcerative colitis, Crohn's disease, and psoriasis. These diseases typically affect the lower portions of the gastrointestinal tract. Psoriasis has symptoms similar to those of an allergy, but psoriasis is a skin disorder and not an allergic reaction. Ulcerative colitis affects the upper portion of the gastrointestinal tract and has similar symptoms to those of psoriasis. Regardless of these driving factors, there are certain challenges that could limit the future development of the market. For instance, there is the availability of alternatives to TNF inhibitor drugs, which could impede growth of the tumor necrosis factor (TNF) inhibitor drugs market. Besides, high production costs pertaining to TNF drugs can also limit market growth.

People around the world are becoming aware of the benefits offered by TNF inhibitor drugs. With growing geriatric population, the demand for TNF inhibitor drugs is likely to increase. Elderly people are more likely to suffer different types of chronic and autoimmune disorders, which would require immediate medical assistance. Hence, such factors could potentially stimulate growth of the tumor necrosis factor (TNF) inhibitor drugs market in the near future.  Recently, in June 2020, Novartis received the U.S. Food and Drug Administration (FDA) approval for its Cosentyx for the treatment of active non-radiographic axial spondyloarthritis.